tecartus
(Brexucabtagene Autoleucel)Kite Pharma, Inc.
Usage: Tecartus is a CD19-directed CAR-T cell immunotherapy for adults with relapsed or refractory mantle cell lymphoma (MCL) or relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).